Predicting stroke mortality

Jickling, Glen C.; Foerch, Christian

doi:10.1212/01.wnl.0000436949.75473.79

Cited by 7 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BNP plasma and NT-proBNP serum levels are elevated in stroke pathology ( Table 1 ) and associated with increased mortality [ 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 ]. Montaner J. et al [ 104 ] identified that BNP plasma levels were higher among patients who died (118.2 vs. 60.9 pg/mL; p < 0.001), and multivariate logistic regression analysis indicated that the plasma BNP level was an independent predictor of death after stroke (BNP > 65.3 pg/mL; odds ratio (OR) = 1.97; p = 0.034).…”

Section: B-type Natriuretic Peptide Expression In Stroke Pathologymentioning

confidence: 99%

B-Type Natriuretic Peptide as a Significant Brain Biomarker for Stroke Triaging Using a Bedside Point-of-Care Monitoring Biosensor

et al. 2020

View full text Add to dashboard Cite

Stroke is a widespread condition that causes 7 million deaths globally. Survivors suffer from a range of disabilities that affect their everyday life. It is a complex condition and there is a need to monitor the different signals that are associated with it. Stroke patients need to be rapidly diagnosed in the emergency department in order to allow the admission of the time-limited treatment of tissue plasminogen activator (tPA). Stroke diagnostics show the use of sophisticated technologies; however, they still contain limitations. The hidden information and technological advancements behind the utilization of biomarkers for stroke triaging are significant. Stroke biomarkers can revolutionize the way stroke patients are diagnosed, monitored, and how they recover. Different biomarkers indicate different cascades and exhibit unique expression patterns which are connected to certain pathologies in the human body. Over the past decades, B-type natriuretic peptide (BNP) and its derivative N-terminal fragment (NT-proBNP) have been increasingly investigated and highlighted as significant cardiovascular biomarkers. This work reviews the recent studies that have reported on the usefulness of BNP and NT-proBNP for stroke triaging. Their classification association is also presented, with increased mortality in stroke, correlation with cardioembolic stroke, and an indication of a second stroke recurrence. Moreover, recent scientific efforts conducted for the technological advancement of a bedside point-of-care (POC) device for BNP and NT-proBNP measurements are discussed. The conclusions presented in this review may hopefully assist in the major efforts that are currently being conducted in order to improve the care of stroke patients.

show abstract

Section: B-type Natriuretic Peptide Expression In Stroke Pathologymentioning

confidence: 99%

B-Type Natriuretic Peptide as a Significant Brain Biomarker for Stroke Triaging Using a Bedside Point-of-Care Monitoring Biosensor

et al. 2020

View full text Add to dashboard Cite

show abstract

“…BNP, a well-known biomarker for heart failure (HF), has now been identified as potentially useful for stroke patient prognostic and recovery management. BNP elevated serum levels in stroke patients show correlation with CEI stroke [90,[123][124][125][126][127][128][129][130][131][132][133][134][135], increased mortality [136][137][138][139][140][141][142][143] and indication of second stroke recurrence [144][145][146]. Cobas h 232 technology is based upon an immunological method and uses 150μL heparinized venous whole blood as sample material.…”

Section: Cobas® H 232 (Roche)mentioning

confidence: 99%

Rapid Point-of-Care-Tests for Stroke Monitoring

2019

Organic Bioelectronics for Life Science and Healthcare

View full text Add to dashboard Cite

Stroke contributes to at least 7 million deaths annually and is the second leading cause of death globally. Ischemic stroke is the most common type of stroke where an interruption of blood flow within brain tissues can lead to cessation of brain activities. Central to existing reperfusion treatment strategies is prompt restoration of blood supply to compromised brain tissues. Existing methods of monitoring the progress of stroke evolution are limited to clinical evaluation and neuroimaging techniques. With advances in biomarker research, there is now a growing interest in the use of stroke biomarkers to guide clinical decision-making, especially for on-site biomarker measurements, to make time-sensitive decisions on stroke prognosis. This chapter presents an overview on pointof-care-tests (POCT) used to guide stroke prognosis, with the aim of shortening time-totreatment, classifying stroke subtypes and improving patient's outcome. First, the current stroke monitoring workflow is presented, which highlights gaps for an improved bedside biomarker assessment. Second, a detailed overview on the different POCTs used for

show abstract

“…However, BNP measurement can also be valuable for stroke patient’s recovery. BNP elevated serum levels in stroke patients also show a correlation with increased mortality [115,116,117,118,119,121,122,124] and indication of second stroke recurrence [110,111,156]. By monitoring BNP levels in stroke patients in their recovery process, the clinical staff will be able to better understand the stroke patient's status by predicting mortality and preventing second stroke recurrence.…”

Section: Pocts Expedite Stroke Prognosticsmentioning

confidence: 99%

“…Glial cells’ origin stroke biomarkers include Protein S100-Beta (S100B) [157,158,161,162,163,164,165], Glial Fibrillary Acidic Protein (GFAP) [157,161,162,166,167,168,169,170,171] and Myelin Basic Protein (MBP) [172,173,174,175], whereas that for Neuronal cells include, Neuron-Specific Enolase (NSE) [129,157,158,161,162,163,166,176,177], Ubiquitin Carboxyl-terminal Hydrolase L1 (UCH-L1) [157,158,178,179,180,181] and Creatine Kinase-BB (CK-BB) [182,183]. On the other hand, Heart muscle cells (cardiomyocytes) include B-Type Natriuretic Peptide (BNP) [87,100,101,102,103,104,105,106,107,108,110,111,112,113,114,115,116,117,118,119,120,121,…”

Section: Key Elements In Novel Stroke-poctsmentioning

confidence: 99%

Point-of-Care-Testing in Acute Stroke Management: An Unmet Need Ripe for Technological Harvest

et al. 2017

View full text Add to dashboard Cite

Stroke, the second highest leading cause of death, is caused by an abrupt interruption of blood to the brain. Supply of blood needs to be promptly restored to salvage brain tissues from irreversible neuronal death. Existing assessment of stroke patients is based largely on detailed clinical evaluation that is complemented by neuroimaging methods. However, emerging data point to the potential use of blood-derived biomarkers in aiding clinical decision-making especially in the diagnosis of ischemic stroke, triaging patients for acute reperfusion therapies, and in informing stroke mechanisms and prognosis. The demand for newer techniques to deliver individualized information on-site for incorporation into a time-sensitive work-flow has become greater. In this review, we examine the roles of a portable and easy to use point-of-care-test (POCT) in shortening the time-to-treatment, classifying stroke subtypes and improving patient’s outcome. We first examine the conventional stroke management workflow, then highlight situations where a bedside biomarker assessment might aid clinical decision-making. A novel stroke POCT approach is presented, which combines the use of quantitative and multiplex POCT platforms for the detection of specific stroke biomarkers, as well as data-mining tools to drive analytical processes. Further work is needed in the development of POCTs to fulfill an unmet need in acute stroke management.

show abstract

Predicting stroke mortality

Cited by 7 publications

References 11 publications

B-Type Natriuretic Peptide as a Significant Brain Biomarker for Stroke Triaging Using a Bedside Point-of-Care Monitoring Biosensor

B-Type Natriuretic Peptide as a Significant Brain Biomarker for Stroke Triaging Using a Bedside Point-of-Care Monitoring Biosensor

Rapid Point-of-Care-Tests for Stroke Monitoring

Point-of-Care-Testing in Acute Stroke Management: An Unmet Need Ripe for Technological Harvest

Contact Info

Product

Resources

About